Otsuka Holdings Co., Ltd./ADR
OTSKF
|
$38.358
-11.7%
100
|
Health Technology
(0.0% 1d) (0.0% 1m) (8.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (0.0% volume)
Earnings Calendar:
Market Cap: $ 21,397,458,597
http://www.otsuka.com
Sec Filling | Patents | n/a employees
(JP) Otsuka Holdings Co., Ltd. engages in the manufacture and sale of pharmaceuticals and nutritional supplements. It operates through the following business segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products segment sells mineral water, food, and beverages. Its products include Bon Curry, Mannan Hikari, and ReSOLA. The Others segment distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded in1950 and is headquartered in Tokyo, Japan.
diagnostics infectious disease nervous system optical
add to watch list Paper trade email alert is off
Concert Pharmaceuticals, Inc.
CNCE
|
$8.37
0.36%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.76% volume)
Earnings Calendar: 2023-03-02
Market Cap: $ 520,711,745
http://www.concertpharma.com
Sec Filling | Patents | 70 employees
(US) Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
autoimmunity nervous system molecule drugs
add to watch list Paper trade email alert is off
Endo International plc
ENDP
|
$0.2926
-9.6%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-5.0% 3d) (0.0% 7d) (97.63% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 68,802,809
http://www.endo.com
Sec Filling | Patents | 3172 employees
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.
cardiovascular women health nervous system women brands msa injection
add to watch list Paper trade email alert is off
Karuna Therapeutics, Inc.
KRTX
|
$329.83
0.0%
1.9M
|
Health Technology
(0.0% 1d) (0.0% 1m) (63.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (672.96% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 12,599,265,884
http://www.karunatx.com
Sec Filling | Patents | 19 employees
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders.The company was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.
nervous system msa schizophrenia
add to watch list Paper trade email alert is off
China Pharma Holdings, Inc.
CPHI
|
$0.3158
-3.63%
4.88%
440K
|
Health Technology
(0.0% 1d) (-7.7% 1m) (-9.2% 1y) (0.0% 2d) (0.0% 3d) (-6.4% 7d) (3599.07% volume)
Earnings Calendar:
Market Cap: $ 4,679,166
http://www.chinapharmaholdings.com
Sec Filling | Patents | 242 employees
(China (Mainland)) China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. It caters people with cardiovascular, central nervous system, infectious, and digestive diseases. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.
cardiovascular china nervous system
add to watch list Paper trade email alert is off
Voyager Therapeutics, Inc.
VYGR
|
$7.5
-0.66%
-0.67%
520K
|
Health Technology
(0.0% 1d) (-27.1% 1m) (-4.9% 1y) (0.0% 2d) (-2.5% 3d) (-9.5% 7d) (29.26% volume)
Earnings Calendar: 2024-03-05
Market Cap: $ 407,254,703
http://www.voyagertherapeutics.com
Sec Filling | Patents | 185 employees
(US) Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
gene therapies nervous system msa aav capsids treatment
add to watch list Paper trade email alert is off
Omeros Corporation
OMER
|
$3.045
-5.14%
-5.42%
390K
|
Health Technology
(0.0% 1d) (-11.4% 1m) (-35.9% 1y) (0.0% 2d) (0.0% 3d) (-1.2% 7d) (13.6% volume)
Earnings Calendar: 2024-03-11
Market Cap: $ 176,435,506
http://www.omeros.com
Sec Filling | Patents | 258 employees
(US) Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
nervous system msa
Drugs
Omidria (phenylephrine and ketorolac)add to watch list Paper trade email alert is off
Stoke Therapeutics, Inc.
STOK
|
$12.08
3.69%
3.56%
1M
|
Health Technology
(0.0% 1d) (95.7% 1m) (37.7% 1y) (0.0% 2d) (0.0% 3d) (-4.0% 7d) (101.62% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 559,349,215
http://www.stoketherapeutics.com
Sec Filling | Patents | 56 employees
(US) Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
eye liver nervous system genetic treatment kidney
add to watch list Paper trade email alert is off
electroCore, Inc.
ECOR
|
$6.0
6.38%
6.0%
7.4K
|
Health Technology
(0.0% 1d) (-11.5% 1m) (-15.6% 1y) (0.0% 2d) (0.0% 3d) (-0.5% 7d) (-54.5% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 36,015,768
http://www.electrocore.com
Sec Filling | Patents | 51 employees
(United States) electroCore, Inc. is a commercial stage medical device company, which engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats, and Thomas J. Errico in September 2005 and is headquartered in Basking Ridge, NJ.
nervous system
add to watch list Paper trade email alert is off
Axsome Therapeutics, Inc.
AXSM
|
$67.91
3.33%
3.22%
890K
|
Health Technology
(0.0% 1d) (-16.7% 1m) (-7.8% 1y) (0.0% 2d) (0.0% 3d) (-3.7% 7d) (78.63% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 3,217,193,806
http://www.axsome.com
Sec Filling | Patents | 45 employees
(US) Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
nervous system
add to watch list Paper trade email alert is off
Sage Therapeutics, Inc.
SAGE
|
$13.35
2.42%
2.36%
1.3M
|
Health Technology
(0.0% 1d) (-36.1% 1m) (-73.1% 1y) (0.0% 2d) (0.0% 3d) (-18.0% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-14
Market Cap: $ 802,424,271
http://www.sagerx.com
Sec Filling | Patents | 675 employees
(US) SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
depression nervous system treatment
Drugs
Zulresso (brexanolone)add to watch list Paper trade email alert is off
Vanda Pharmaceuticals Inc.
VNDA
|
$5.11
2.82%
2.74%
2.4M
|
Health Technology
(0.0% 1d) (37.9% 1m) (-15.3% 1y) (0.0% 2d) (0.0% 3d) (29.1% 7d) (Infinity% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 294,016,620
http://www.vandapharma.com
Sec Filling | Patents | 284 employees
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
dermatitis schizophrenia nervous system atopic dermatitis
Drugs
Fanapt (iloperidone)Hetlioz (tasimelteon)
Hetlioz LQ (tasimelteon)
add to watch list Paper trade email alert is off
Sangamo Therapeutics, Inc.
SGMO
|
$0.5143
6.02%
5.68%
1M
|
Health Technology
(0.0% 1d) (-36.3% 1m) (-68.1% 1y) (0.0% 2d) (0.0% 3d) (-3.7% 7d) (17.79% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 92,011,536
http://www.sangamo.com
Sec Filling | Patents | 354 employees
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.
gene therapies genomic autoimmunity genome editing urea immunology t-cell nervous system metabolic ceiling
add to watch list Paper trade email alert is off
Regulus Therapeutics Inc.
RGLS
|
$2.13
-4.05%
-4.23%
220K
|
Health Technology
(0.0% 1d) (-11.2% 1m) (85.0% 1y) (0.0% 2d) (-5.1% 3d) (-20.1% 7d) (-31.3% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 139,440,985
http://www.regulusrx.com
Sec Filling | Patents | 21 employees
(US) Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
autonomous kidney diseases renal hepatitis antiviral nervous system clinical trials treatment kidney
add to watch list Paper trade email alert is off
Taysha Gene Therapies, Inc.
TSHA
|
$2.265
-6.02%
-6.4%
1.8M
|
Health Technology
(0.0% 1d) (-18.6% 1m) (234.7% 1y) (0.0% 2d) (-1.6% 3d) (-9.4% 7d) (40.87% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 423,596,393
http://www.tayshagtx.com
Sec Filling | Patents | 38 employees
Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.
gene therapies nervous system aav capsids treatment
add to watch list Paper trade email alert is off
ACADIA Pharmaceuticals Inc.
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
(0.0% 1d) (-7.8% 1m) (-13.8% 1y) (0.0% 2d) (0.0% 3d) (1.9% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,771,456,983
http://www.acadia-pharm.com
Sec Filling | Patents | 503 employees
(US) ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
nervous system parkinson msa treatment
add to watch list Paper trade email alert is off
Intra-Cellular Therapies Inc.
ITCI
|
News
0
d
|
$72.29
0.4%
0.4%
2.2M
|
Health Technology
(0.0% 1d) (10.4% 1m) (22.0% 1y) (0.0% 2d) (-4.8% 3d) (13.1% 7d) (NaN% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 6,998,191,837
http://www.intracellulartherapies.com
Sec Filling | Patents | 330 employees
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
neurodegenerative schizophrenia glass alzheimer heavy drug nervous system neuropsychiatric molecule drugs neurological msa treatment alzheimer’s
add to watch list Paper trade email alert is off
Anavex Life Sciences Corp.
AVXL
|
$3.8
0.0%
2.1M
|
Health Technology
(0.0% 1d) (-25.8% 1m) (-52.3% 1y) (0.0% 2d) (0.0% 3d) (-10.2% 7d) (NaN% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 312,027,542
http://www.anavex.com
Sec Filling | Patents | 16 employees
(US) Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
neurodegenerative alzheimer nervous system parkinson treatment alzheimer’s
add to watch list Paper trade email alert is off
vTv Therapeutics Inc.
VTVT
|
$24.74
-0.21%
2K
|
Health Technology
(0.0% 1d) (-7.2% 1m) (3242.3% 1y) (0.0% 2d) (2.4% 3d) (-1.0% 7d) (-79.25% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 60,188,882
http://www.vtvtherapeutics.com
Sec Filling | Patents | 26 employees
(US) vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
diabetes cancer diabetic alzheimer nervous system molecule drugs metabolic treatment glioblastoma
add to watch list Paper trade email alert is off
Supernus Pharmaceuticals, Inc.
SUPN
|
$29.43
1.94%
1.9%
360K
|
Health Technology
(0.0% 1d) (-17.2% 1m) (-22.9% 1y) (0.0% 2d) (-0.4% 3d) (-3.7% 7d) (-11.66% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,610,849,755
http://www.supernus.com
Sec Filling | Patents | 464 employees
(US) Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
nervous system neurological treatment 3d
Drugs
OXTELLAR XR (OXCARBAZEPINE)Trokendi XR (topiramate)
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
BCDA | $0.377 -1.4% 97K
|
Health Technology
|
22:00
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10